DK1842550T3 - Composition for Induction of Immune Tolerance - Google Patents

Composition for Induction of Immune Tolerance

Info

Publication number
DK1842550T3
DK1842550T3 DK07105399.5T DK07105399T DK1842550T3 DK 1842550 T3 DK1842550 T3 DK 1842550T3 DK 07105399 T DK07105399 T DK 07105399T DK 1842550 T3 DK1842550 T3 DK 1842550T3
Authority
DK
Denmark
Prior art keywords
induction
composition
immune tolerance
immune
tolerance
Prior art date
Application number
DK07105399.5T
Other languages
Danish (da)
Inventor
Oosterhout Antonius Josephus Maria Van
Martien Lukas Kapsenberg
Frank Reinoud Weller
Yousef Al-Madane Taher
Esch Elisabeth Catharina Adriana Maria Lobato-Van
Joost Lambert Max Vissers
Original Assignee
Hal Allergy Holding B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hal Allergy Holding B V filed Critical Hal Allergy Holding B V
Application granted granted Critical
Publication of DK1842550T3 publication Critical patent/DK1842550T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK07105399.5T 2003-03-28 2004-03-25 Composition for Induction of Immune Tolerance DK1842550T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03075909A EP1462111A1 (en) 2003-03-28 2003-03-28 Composition for inducing immunotolerance
EP04723429A EP1608391A2 (en) 2003-03-28 2004-03-25 Composition for inducing of immunotolerance

Publications (1)

Publication Number Publication Date
DK1842550T3 true DK1842550T3 (en) 2013-04-22

Family

ID=32798967

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07105399.5T DK1842550T3 (en) 2003-03-28 2004-03-25 Composition for Induction of Immune Tolerance

Country Status (8)

Country Link
US (1) US20060057154A1 (en)
EP (4) EP1462111A1 (en)
CA (1) CA2518793A1 (en)
DK (1) DK1842550T3 (en)
ES (1) ES2403074T3 (en)
PL (1) PL1842550T3 (en)
PT (1) PT1842550E (en)
WO (1) WO2004084927A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0732929B1 (en) * 1993-10-29 2008-05-14 The Brigham And Women's Hospital, Inc. Therapeutic use of cis-element decoys in vivo
US7378509B2 (en) * 2003-12-02 2008-05-27 Anesiva, Inc. NF-kappaB oligonucleotide decoy molecules
AU2005286640A1 (en) * 2004-09-21 2006-03-30 Anesiva, Inc. Delivery of polynucleotides
US20060253100A1 (en) 2004-10-22 2006-11-09 Medtronic, Inc. Systems and Methods to Treat Pain Locally
EP1723965A1 (en) 2005-05-18 2006-11-22 Stallergenes Sa Compositions for antigen-specific induction of immuno-tolerance via oral immunization
CN101646418B (en) * 2006-10-12 2013-07-17 昆士兰大学 Compositions and methods for modulating immune responses
WO2008043157A1 (en) 2006-10-12 2008-04-17 The University Of Queensland Compositions and methods for modulating immune responses
WO2008080195A1 (en) * 2006-12-29 2008-07-10 The University Of Queensland Compositions and methods for treating or preventing unwanted immune responses
WO2008150899A1 (en) * 2007-05-29 2008-12-11 Emory University Combination therapies for treatment of cancer and inflammatory diseases
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US20100239632A1 (en) 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
WO2012064657A1 (en) * 2010-11-08 2012-05-18 The Board Of Trustees Of The Leland Stanford Junior University Serum amyloid a (saa) overrides regulatory t cells (treg) anergy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9203535D0 (en) * 1992-02-19 1992-04-08 Leo Pharm Prod Ltd Novel treatment iii
AU2670995A (en) * 1994-05-26 1995-12-21 Innogenetics N.V. New methods and compounds for the selective modulation of antigen-specific t-cell responsiveness

Also Published As

Publication number Publication date
CA2518793A1 (en) 2004-10-07
EP1842550A2 (en) 2007-10-10
ES2403074T3 (en) 2013-05-13
PT1842550E (en) 2013-03-27
EP1772152A2 (en) 2007-04-11
EP1842550A3 (en) 2008-12-10
WO2004084927A3 (en) 2005-01-27
PL1842550T3 (en) 2013-06-28
EP1608391A2 (en) 2005-12-28
EP1772152A3 (en) 2007-06-27
EP1462111A1 (en) 2004-09-29
EP1842550B1 (en) 2013-01-16
US20060057154A1 (en) 2006-03-16
WO2004084927A2 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
DK1828164T3 (en) Process for the preparation of N-phenylpyrazole-1-carboxamides
DK1778668T3 (en) Process for the preparation of dihydropteridione
DK2206517T3 (en) Immunopotentiating compositions comprising anti-PD-L1 antibodies
DK1608634T3 (en) PROCEDURES FOR INSULATING CRYSTALLINIC FORM OF 5-AZACYTIDINE
DK2141204T3 (en) Process for the preparation of bituminous compositions
DK1794174T3 (en) PROCEDURES AND COMPOSITIONS FOR INHIBITING CURRENT IMMUNE RESPONSES AND AUTO-IMMUNITY
DK1678208T3 (en) REMOVAL OF HIGH MOLECULAR WEIGHT AGGREGATES USING HYDROXYAPATITE CHROMATOGRAPHY
DK1575416T3 (en) PROCEDURES FOR DIAGNOSTICING PRECLAMPSY
DK3395339T3 (en) QUICK SOLVING FORMULATION OF CINACALCET-HCL
DK2363414T3 (en) Site-directed modification of FVIII
DK1802579T3 (en) Derivatives of 3-arylaminopyridine
DK1406656T3 (en) Methods for administering anti-TNF alpha antibodies
DE602005013349D1 (en) OPTICAL SILICON COMPONENT
DK1637610T3 (en) Process for the preparation of alkyl esters
DK2402005T3 (en) Sustained-release formulations of nalbuphine
DK1542725T3 (en) PROCEDURE FOR HUMANIZING IMMUNE SYSTEM MOLECULES
DK1840125T3 (en) Intermediates for the preparation of dioxane-2-alkylcarbamates
DK1417180T3 (en) Preparation of Aminopyrimidine Compounds
DK1587542T3 (en) Use of anti-CD100 antibodies
DK1716119T3 (en) ANALOGS OF BENZOQUINON-CONTAINING ANAMICYCINES FOR TREATMENT OF CANCER
DK1350765T3 (en) Method of Preparation of Iron Oxides
DE502004010591D1 (en) SYNCHRONIZER RING
DK1831223T3 (en) Process for the preparation of L-biopterin
DK1516540T3 (en) Use of vitamin D compounds
DK1842550T3 (en) Composition for Induction of Immune Tolerance